Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones | Zendy

David S. Goldfarb | Zendy; Patricia MacDonald | Zendy; Lhanoo Gunawardhana | Zendy; Solomon Chefo | Zendy; Lachy McLean | Zendy

Open Access

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Author(s) -

David S. Goldfarb,

Patricia MacDonald,

Lhanoo Gunawardhana,

Solomon Chefo,

Lachy McLean

Publication year - 2013

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01760213

Subject(s) - febuxostat , medicine , allopurinol , uric acid , placebo , gout , urology , excretion , urinary calcium , urinary system , creatinine , renal function , hyperuricemia , pathology , alternative medicine

Higher urinary uric acid excretion is a suspected risk factor for calcium oxalate stone formation. Febuxostat, a xanthine oxidoreductase inhibitor, is effective in lowering serum urate concentration and urinary uric acid excretion in healthy volunteers and people with gout. This work studied whether febuxostat, compared with allopurinol and placebo, would reduce 24-hour urinary uric acid excretion and prevent stone growth or new stone formation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research